Skip to main content
. 2021 Oct 4;16(3):689–715. doi: 10.1177/19322968211042656

Figure 5.

Figure 5.

Forest plot comparison of the dose dependent relationship between SGLT2 inhibitor use and the incidence of DKA. Compared with placebo, SGLT2 inhibitors were associated with an increased risk of DKA (RR 2.81, 95% CI: 1.97 to 4.01, P < .001). 38 comparisons were made of 7,396 participants; trial durations ranged from 1 to 52 weeks. Figure reproduced from Musso et al 108 under the Creative Commons Attribution 4.0 International License.